Pharmaceutical & Biotech
News and Insights
GSK to stop US sales of VPV vaccine
Citing low market demand, GlaxoSmithKline has decided to stop US sales of their HPV vaccine Cervarix. Original goals were to have 80% of girls and boys vaccinated by 2020. Current rates are falling well short of that goal with only 40% of girls and just 21% of boys currently vaccinated. The move gives Merck complete control of the U.S. HPV vaccine market as public health officials push for higher HPV vaccination rates. Click here to view the entire article. ...
FDA oks Philips’ smartphone plug-in for cardiac imaging
The FDA has given the ok for Philips to add a cardiac transducer to its Lumify package. This portable diagnostic device already allows for doctors to scan gallbladders and lungs. Now doctors will be able to execute quick high quality images for routine cardiac exams. The new S4-1 cardiac transducer weighs less than a smartphone and joins the existing two transducers for use in emergency care, critical care and ambulances, according to the statement. Lumify's low cost and portability allows doctors in emergency situations to quickly triage patients without needing to locate and procure an ultrasound cart, Philips said in the statement. Click here to view the entire article. ...
What do you do when you have received a counter-offer?
After you have submitted your resignation to your current company, as a valued member of their team there is always a chance that they will provide you with a counter offer. Here are the top reasons not to accept: After resigning, you have made your employer aware that you were looking for a new opportunity. This may question your loyalty going forward. It is important to consider the above mentioned point for when any promotions / pay rises are pending in your current company. The fact that you had previously tendered your resignation could go against you. Again, back to loyalty, if any strategic decisions are being made such as redundancies, company loyalty may again play a major factor regarding who will stay and who will go. You must consider why such an offer was not made during your employment and why they are only offering you such incentives at the last minute. The same circumstances that now cause you to consider making a change almost always reoccur within the next 6-12 months. Statistics show that if you accept a counter-offer, the probability of voluntarily leaving in 6 months or being let go within 1 year are extremely high. Once ...
Specialty pharmacies seeing growth
A little-noticed piece of the pharmaceutical supply chain is seeing tremendous growth in the private sector. A dozen of specialty pharmacies have made it onto the Inc. 5000 list of the fastest growing companies in the US, with Pantherx Specialty Pharmacy making it in the top ten with revenues toping $42 million. Pantherx Specialty Pharmacy, which was founded in 2012, focuses on rare and orphan drugs, delivering drugs to very small patient groups. Click here to view the entire article. ...
BARDA funding Zika vaccine
We are only scratching the surface of the long term effects of the Zika virus. Currentyly many companies are diligently working to create a vaccine to prevent the disease all together. To date, The Biomedical Advanced Research and Development Authority (BARDA) have committed $433 million in funds to fight the Zica virus. Most recently awarding Sanofi Pasteur $43 million to help fund Phase II development of its Zika vaccine, named Zika purified inactivated virus (ZPIV). If the Phase II testing is successful, BARDA could give another $130 million for further studies. Click here to read more about the Zika vaccine research. ...
Pfizer wants black-box warning removed
Pfizer is fighting to have the black-box warning due to neuropsychiatric side effects removed from its stop-smoking drug Chantix. Recently, Pfizer completed an 8,000 patient study comparing Chantix to GSK's Zyban and to nicotine patch therapy. The study included patients with and without a history of mental illness. It concluded that the drug did not significantly increase the risk of neuropsychiatric side effects. However, FDA scientists aren't so quick to agree with the results. They cited inconsistencies in the data-collection methods and the characterization of some side effects of the medication. Click here to view the entire article. ...
Allergan's CEO says no big price increases
In a time when pharmaceutical companies are raising rates multiple times a year and with double and triple digit increases, Allergan's CEO, Brent Sounders, has said they will limit price increases. When they do increase prices, it will be just once a year and the increase will be in the single digits. This is welcomed news as many pharmaceutical companies have been under fire recently for skyrocketing prescription drug costs. Click here to view the entire article. ...
Mylan to launch a generic to EpiPen
It has been an interesting week for Mylan who last week raised the cost of its 2-pack of EpiPens to an astonishing $600. The company received immediate backlash from patients, doctors and congress. After refusing to reduce the price, Mylan last Thursday offered $300 in EpiPen out-of-pocket assistance at the pharmacy for patients. Now the company has announced it plans to launch a generic in the upcoming weeks. The cost of the generic 2-pack would be $300. While this is welcomed news, it does not help all the families who have already had to purchase high priced pens for their children who are heading back to school or explain why the cost of the pens have increased from $100 in 2009 to $600 just 7 years later. Click here to view the entire article. ...
Pfizer to close four distribution sites
Pfizer has seen significant revenue increases from its $15 billion buyout of Hospira last year. Q2 earnings show an 11% increase in revenue. With this good news, comes a little bit of bad news as Pfizer also announced that it will close the legacy distribution centers that were part of last year's buyout. Centers will close in Atlanta, Dallas, Los Angeles and King of Prussia, PA. Distribution from those sites will move to centers in Memphis and Pleasant Prairie, WI. When all is said and done, just over 100 jobs will be lost. Click here to view this entire article. ...
Allergan plans new US Headquarters in New Jersey
Allergan was eyeing a move to Lansdale, PA but has decided to relocate its US headquarters to Madison, NJ. The plan includes combining its Parsippany location with three other operations throughout the state to help the company better collaborate and be more efficient. The new location in Madison used to house Pfizer before it was sold 2014. The renovations and move is expected to be done by the end of 2017. This will keep over 1,000 jobs in New Jersey and create nearly 300 more. Click here to view the entire article. ...
1 of 4